Summary The effect of chemotherapy on the serum lipid mobilising activity of a group of cancer patients with or without weight loss has been determined. The pre-treatment level of serum lipolytic activity in all cancer patients, with or without weight loss, was higher than normal controls (0.22±0.01 versus 0.06+ 0.01 jAmol glycerol released ml-' serum respectively). The pre-treatment levels of lipid mobilising activity in the patients serum was proportional to the extent of weight loss (correlation coefficient 0.81), if the extent of weight loss was small (<14 kg). Patients who showed a positive response to chemotherapy also showed a decrease in their plasma levels of lipolytic activity, while a patient who showed no response to therapy also showed no change in the serum lipolytic activity. There was no correlation between the serum lipolytic activity and response to megestrol acetate, a synthetic orally active progestogen, which is currently under investigation as an anticachectic agent. Serum from cancer patients showed lipolytic activity which was retained on a DEAE cellulose column and eluted by a salt gradient, in contrast with normal controls. Response to chemotherapy was associated with a decrease of the retained material, although the profile did not return to the normal state. These results need confirmation in a larger group of patients using more specific methods to determine tumour lipolytic activity, but suggest that it may be possible to monitor response to therapy by measurement of the serum lipolytic activity.
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Loss of body fat accounts for the major portion of weight loss in cancer patients (Heymsfield & McManus, 1985) , and an increased rate of lipolysis appears to precede progressive loss of skeletal muscle in sarcoma-bearing rats (Ekman et al., 1982) . Several factors have been postulated to account for an increased lipid mobilisation in the tumour-bearing state. These can be divided into direct lipid mobilising factors such as toxohormone L (Masuno et al., 1981) , a serum factor produced by a thymic lymphoma in AKR mice (Kitada et al., 1980 (Kitada et al., , 1981 and a serum factor produced by a cachexiainducing murine colonic tumour (MAC16) (Beck & Tisdale, 1987) , and indirect factors such as tumour necrosis factor (TNF), which is thought to stimulate breakdown of adipose tissue as a result of the inhibition of the enzyme lipoprotein lipase, thus blocking synthesis of triglycerides (Oliff, 1988) . Using chromatographic characterisation we have recently shown that the lipid mobilising factor found in the serum and urine of animals bearing the MAC16 tumour is also present in the serum and urine of humans with clinical cancer cachexia (Beck & Tisdale, in preparation) . In cancer patients the level of this factor appears to correlate directly with the extent of weight loss, although even patients without weight loss have significantly elevated serum lipolytic activity when compared with non-cancer controls. This suggests that the lipid mobilising factor may be related to the tumour-bearing state and that alteration in the level may occur in response to therapy. If this is correct it could provide an alternative measurement of the response of tumours to therapy. The present report documents the effect of therapy on the serum lipolytic activity of a diverse group of cancer patients, with and without weight loss, at the time of initiation of treatment.
Materials and methods

Subjects
Thirteen patients, seven male and six female with histologically proven malignancy and various degrees of weight loss were entered into the study (Table I) where 1 = much less than usual and 5 = much more than usual. The second determination was from a 10 cm linear analogue scale where 0 = no intake and 10 = much more than normal.
Chromatographic characterization Serum samples (1 ml) were fractionated by anion exchange chromatography using a DEAE cellulose column (dimensions 1.6 x 30 cm) equilibrated with 10 mM phosphate, pH 8.0. Active material was eluted from the column using a linear gradient of 0.08 -0.2 M NaCl in 10 mM phosphate, pH 8.0. The column was eluted at a flow rate of 30 ml h-' and the effluent was assayed for lipolytic activity.
Determination of lipolytic activity Mice (strain BKW) were killed by cervical dislocation and their epididymal adipose tissue was removed and placed in isotonic saline, minced and incubated at 37°C for 2 h in Krebs Ringer bicarbonate buffer, pH 7.2, containing 2 mg ml-' of collagenase (Sigma Chemical Co., Dorset, UK) with prior gassing with 95% 02:5% C02. Digestion of the tissues was detected by the disappearance of intact pieces and an increased turbidity of the medium. Undigested material and non-adipose matter was removed by allowing the fat cells to float to the surface of the buffer and the infranatant was aspirated and replaced with fresh buffer. The washing procedure was repeated three times to remove all collagenase, non-adipose cells and any endogenous hormones. After the (100yl) were assayed in duplicate and the assay was repeated 4-5 times on each sample at different times. At the end of the incubation period 0.5 ml of the incubation buffer was added to 0.5 ml of 10% (w/v) perchloric acid and the mixture was shaken to ensure deproteinisation. The precipitated protein was sedimented by centrifugation at 2,000 r.p.m. for 10 min, the supernatant removed and neutralised with 20% (w/v) KOH, after which the potassium perchlorate was sedimented by centrifugation (2,000 r.p.m., 10 min) and the volume of the supernatant was recorded and used to calculate the dilution factor. Assays on the supernatant were performed either immediately, or after storage at -20°C for between 18 and 72 h. The concentration of glycerol was determined enzymatically on 200 gl aliquots of the supernatant by the method of Wieland (1974 
Results
The characteristics of the patients employed in this study is given in Table I and the serum lipolytic activity before and after treatment is shown in Table II . The pre-treatment levels of serum lipolytic activity in all patients with or without weight loss were higher than normal controls (0.22 ± 0.01 versus 0.06 ± 0.01 jsmol glycerol released ml-' serum respectively) or patients with Alzheimer's disease and weight loss (0.11 ± 0.02 1tmol glycerol released ml' serum (P < 0.001)).
The pre-treatment levels of serum lipolytic activity increase as the weight loss increases for patients with weight loss up to 14 kg (Figure 1 , r = 0.81) but do not correlate with higher weight loss.
The patients can be divided into two groups according to the type of treatment. Patients 1 to 8 (Table II) were given either radiotherapy or chemotherapy with curative intent, while patients 10 to 13 had advanced unresponsive tumours and significant weight loss, and were given symptomatic treatment with megestrol acetate (320-1,600 mg m-2) to control weight loss as part of an ongoing clinical trial. Patients 1, 2, 3, 5, 7 and 8 showed a significant decrease in the plasma levels of lipolytic activity, either during or after treatment, and all showed a response to antitumour therapy. Posttreatment serum levels of lipolytic activity in patients 1 and 2 and values for 1 and 7 during treatment were not significantly different from normal controls.
In contrast, patient 4 showed no alteration in serum lipolytic activity either during or after treatment and showed no response to chemotherapy. Only patient 6 showed an alteration in serum lipolytic activity opposite to that expected from the tumour response to therapy. Thus, although there was a marked clinical response to treatment, the serum lipolytic activity apparently increased. This patient was also receiving warfarin (4-5 mg day-') which may have interfered with the lipolytic assay. In separate experiments, we have shown warfarin to markedly increase the apparent glycerol concentration using the coupled enzyme assay (Wieland, 1974) , especially at low concentrations of glycerol. If this value is excluded the average serum value of lipolytic activity after treatment (0.10 ± 0.02 timol glycerol released ml-') was significantly (P <0.05) lower than the pre-treatment serum level (0.21 ± 0.03 gmol glycerol release ml') for those patients who responded to chemotherapy.
None of the patients given the high dose megestrol acetate exhibited a decreased tumour burden, although patients 9 and 10 did respond symptomatically with a marked increase in appetite and body weight. However, only patient 9 showed unequivocal weight gain, since weight gain in patient 10 was associated with a pleural effusion. All patients except patient 11 increased their food intake in response to megestrol acetate treatment. Patients 11, 12 and 13 showed either no response or progression of their weight loss while receiving megestrol acetate. Serum lipolytic activity was decreased in patients 10 and 12 after treatment with megestrol acetate.
In order to investigate the molecular species responsible for the lipid mobilising activity in the serum of cancer patients and the effect of therapy on activity, we have subjected the serum of a large number of cancer patients and controls to DEAE cellulose chromatography with a salt gradient from 0.08 to 0.2 M NaCl and a representative chromatogram for patient 3 was compared with a representative profile obtained with serum from a normal subject (Figure 2) . Most of the serum lipid mobilising activity in normal subjects was not retained by a DEAE cellulose column and appeared as a single peak at the start of the salt gradient (Figure 2c ). In contrast, serum from the cachectic patients, in addition to an increased total lipid mobilising activity, contained peaks of activity retained by the DEAE cellulose and eluted by the salt gradient. These peaks of lipolytic activity, which appear specific to the cancer cachectic state, and eluting between 0.1 and 0.15 M NaCl were reduced in activity by approximately 40% in response to chemotherapy. However, although the patient had an almost complete response to the therapy there was still an indication that peaks specific to the neoplastic state were present (Figure 2b ). (Beck & Tisdale, 1987) . Here serum lipolytic activity increases with weight loss until the total loss of carcass weight reaches 16% and thereafter decreases with increasing weight loss. The reason for this decrease in serum lipolytic activity with large weight loss is not known.
The function of such a material in tumour growth and weight loss must await its purification and indentification. However, the presence of this material may provide an independent assay system for determining the response of cancer patients to various treatment regimes, and in the present study we have attempted to correlate serum levels with response to therapy. Although we have only utilised serum values in the present study the technique would also be applicable to urine, especially when a more sensitive bioassay system becomes available. Problems arise in the routine detection of lipolytic activity in urine when the urine volume is large, and the concentration of lipolytic factor is below the level of detection in the present bioassay system, or where kidney function is impaired. In order to obtain consistent results with serum it is important that repeat determinations are not done with refrozen specimens.
For patients with various types of tumours receiving chemotherapy or radiotherapy the concentration of serum lipid mobilising factors in general decreased in response to effective therapy. The single exception was a patient with a malignant teratoma, who was also receiving warfarin, which was subsequently shown to interfere with the bioassay. For the other patients the average serum lipolytic activity decreased from 0.21 ± 0.03 to 0.10 ± 0.02 ymol glycerol released ml' (P<0.05) where a response was obtained. A potential problem in the measurement of serum lipolytic activity in patients receiving chemotherapy is the possibility of drug interference in the bioassay. However, confirmation that a specific effect has been obtained can be determined by ion exchange chromatography of the serum before and after treatment. Where a clinical response is observed this is associated with a decrease in the lipid mobilising activity retained by a DEAE cellulose column, although the profile does not return to the normal state.
Megestrol acetate is a synthetic, orally active progestogen, widely used for the therapy of advanced breast cancer. Recently this agent has been shown to produce weight gain in more than 80% of all treated patients, with a subjective improvement in appetite occurring in most patients (Aisner et al., 1988) , and is currently being evaluated for the control of cachexia in cancer. Of the five evaluable patients receiving megestrol acetate two showed a marked increase in body weight accompanied by an increase in both appetite and food intake although only one showed unequivocal weight gain. There was no reduction in tumour mass in either patient and there was definite tumour progression and both died soon after. However, the serum lipolytic activity was significantly reduced in one patient (patient 10). Patient 12 also responded to megestrol acetate with an increase in both appetite and food intake, and although there was no alteration in body weight the serum lipolytic activity was also reduced. The only two patients to show a decrease in serum lipolytic activity with megestrol acetate had high initial values and these patients also had the most marked increase in appetite and food intake. Thus, there seems to be no simple relationship between change in serum lipolytic activity and response to megestrol acetate, although there may be a correlation with food intake. The role of the lipolytic factor and its specificity for the neoplastic state awaits further characterisation.
